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ttp://dx.doi.org/10.1016/j.ajpath.2013.09.017Tumor-associated macrophages (TAMs) exhibit an M2 macrophage phenotype that suppresses anti-tumor
immune responses and often correlates with poor outcomes in patients with cancer. Patients with
ovarian cancer frequently present with peritoneal carcinomatosis, but the mechanisms that induce naïve
peritoneal macrophages into TAMs are poorly understood. In this study, we found an increased abun-
dance of TAMs in mouse i.p. xenograft models of ovarian cancer that expressed HOXA9, a homeobox gene
that is associated with poor prognosis in patients with ovarian cancer. HOXA9 expression in ovarian
cancer cells stimulated chemotaxis of peritoneal macrophages and induced macrophages to acquire
TAM-like features. These features included induction of the M2 markers, CD163 and CD206, and the
immunosuppressive cytokines, IL-10 and chemokine ligand 17, and down-regulation of the immunos-
timulatory cytokine, IL-12. HOXA9-mediated induction of TAMs was primarily due to the combinatorial
effects of HOXA9-induced, tumor-derived transforming growth factor-b2 and chemokine ligand 2 levels.
High HOXA9 expression in clinical specimens of ovarian cancer was strongly associated with increased
abundance of TAMs and intratumoral T-regulatory cells and decreased abundance of CD8þ tumor-
inﬁltrating lymphocytes. Levels of immunosuppressive cytokines were also elevated in ascites ﬂuid of
patients with tumors that highly expressed HOXA9. HOXA9 may, therefore, stimulate ovarian cancer
progression by promoting an immunosuppressive microenvironment via paracrine effects on peritoneal
macrophages. (Am J Pathol 2014, 184: 271e281; http://dx.doi.org/10.1016/j.ajpath.2013.09.017)Supported by Cancer and Prevention Research Institute of Texas grant
RP120390 (H.N.), MD Anderson Cancer Center Institutional Research
grant (H.N.), NIH grants CA141078 (H.N.) and CA111882 (E.L.), and a
Burroughs Wellcome Fund Clinical Scientist Award in Translational
Research (E.L.).It is increasingly recognized that tumor progression is con-
trolled by the dynamic interplay between tumor and stromal
cells, such as ﬁbroblasts, endothelial cells, and immune
cells.1,2 Among the latter, macrophages are a major compo-
nent. Macrophages exhibit diverse functional properties in
response to different microenvironmental cues. Two polar-
ized macrophage phenotypes have been described that are
analogous to the type 1/2 helper T-cell dichotomy of T-cell
responses. On one hand, macrophages that are stimulated
with microbial agents and interferon-g exhibit an M1 (classi-
cally activated) phenotype and express immunostimulatory
cytokines.3,4 On the other hand, stimulation of macrophages
with IL-4, IL-10, or IL-13 induces an M2 (alternatively acti-
vated) phenotype.3,4 M2 macrophages are often characterized
by expression of mannose and scavenger receptors and of
immunosuppressive cytokines and chemokines. One importantstigative Pathology.
.mechanism by which these macrophage-derived factors sup-
press anti-tumor immunity is by stimulating recruitment of T-
regulatory (Treg) cells.3,4 Tumor-associated macrophages
(TAMs) derive from circulating monocyte precursors and are
recruited to tumors. TAMs are widely thought to exhibit an
M2 macrophage phenotype, and are strongly associated with
poor outcomes in patients with a wide variety of cancers.5
However, it is unclear whether tissue-speciﬁc mechanisms
in a particular type of cancer regulate the interaction between
tumor cells and macrophages in the tumor microenvironment.
Ko et alApproximately 75% of patients with epithelial ovarian
cancer present with disease that has already disseminated
throughout the peritoneal cavity at the time of initial diag-
nosis.6,7 Ovarian cancer cells typically spread by exfoliating
into the peritonealﬂuid and implant on the omentum and other
peritoneal surfaces.6,7 Peritoneal carcinomatosis is frequently
associated with the formation of ascites. The peritoneal cavity
normally harbors naïve macrophages that play essential roles
in regulating tissue repair and inﬂammatory responses.
Ovarian cancer cells have been demonstrated to polarize
macrophages toward an M2 phenotype,8,9 but the molecular
mechanisms in ovarian cancer cells that induce this polari-
zation are poorly understood. Because of the unique clinical
behavior of ovarian cancer, we hypothesized that interactions
between ovarian cancer cells and peritoneal macrophages
might be controlled, in part, by tissue-speciﬁc mechanisms
that are activated in ovarian cancer cells.
Homeobox genes encode transcription factors that control
self-renewal and cell differentiation.10,11 The homeobox
gene HOXA9 is normally expressed during development of
the female reproductive tract, and its expression is tightly
regulated in the adult tract.12,13 We recently identiﬁed that
high HOXA9 expression in ovarian cancer is strongly asso-
ciated with poor overall survival and that HOXA9 promotes
ovarian tumor growth in vivo but not in vitro.14 This sug-
gested that HOXA9 promotes tumor growth by modulating
interactions between tumor cells and host cells. In this study,
we demonstrate that expression of HOXA9 in ovarian cancer
cells stimulates chemotaxis of peritoneal macrophages and
elicits TAM-like features. This stimulatory effect of HOXA9
on TAMs was found to be primarily mediated via its induc-
tion of tumor-derived transforming growth factor (TGF)-b2
and chemokine ligand (CCL) 2 levels. These results indicate
that sustained HOXA9 expression in ovarian cancer may
promote disease progression by educating peritoneal mac-
rophages toward a TAM-like phenotype.
Materials and Methods
Abs and Growth Factors
Sources of antibodies (Abs) were as follows: CD68, CD8
(Dako, Glostrup, Denmark), F4/80 (AbD Serotec, Kidling-
ton, UK), CD163 (Leica Microsystems, Buffalo Grove, IL),
CD206 (R&D Systems, Minneapolis, MN), FOXP3 (eBio-
science, San Diego, CA), HOXA9 (Santa Cruz Biotech-
nology, Santa Cruz, CA), and secondary Abs (BD
Biosciences, San Jose, CA). Recombinant TGF-b2 and
CCL2 were purchased from BioLegend (San Diego, CA).
Human Tissue Specimens
Studies using human tissues were reviewed and approved
by the University of Texas MD Anderson Cancer Center
Institutional Research Board (Houston) and the University
of Chicago Institutional Research Board (Chicago, IL). All272specimens of human ovarian cancer tissues and ascites were
delinked from patient identiﬁers. All cases were postmen-
opausal patients with International Federation of Gynecol-
ogy and Obstetrics (FIGO) stage III/IV, high-grade serous
ovarian carcinomas.
Cell Culture
The parental mouse ovarian cancer cell line, MOSEC, has
been previously described15 and was provided by Katherine
Roby (University of Kansas, Lawrence). MOSEC cell lines
that stably express HOX genes and SKOV3ip cell lines that
stably express HOXA9 shRNAs have been previously
described.13,14 MOSEC and SKOV3ip cell lines were cul-
tured in Dulbecco’s modiﬁed Eagle’s medium and McCoy’s
5A medium (Invitrogen, Carlsbad, CA), respectively. The
IC-21 mouse peritoneal macrophage cell line was purchased
from ATCC (Manassas, VA) and cultured in RPMI 1640
medium (Invitrogen). Normal peritoneal macrophages were
isolated from naïve 4-week-old female C57BL/6 mice by
pelvic washing with PBS containing 3% fetal bovine serum
(FBS). Primary cultures of macrophages were maintained in
RPMI 1640 medium. All culture media were supplemented
by addition of 10% FBS and penicillin/streptomycin.
Stimulation of Macrophages with Tumor-Conditioned
Media
Ovarian cancer cells (1.5 106) were seeded in 10-cm dishes
and cultured inmediumcontaining 1%FBS for 2 days. Tumor-
conditioned medium was collected, ﬁltered, and applied to
macrophages. Macrophages were analyzed for expression of
surface markers and cytokines at 5 days thereafter.
Chemotaxis Assays
A total of 60,000 tumor cells per well were seeded in the
lower chamber of 24-well Transwell chambers (BD Bio-
sciences) and allowed to adhere overnight. A total of 50,000
macrophages per well were seeded in the upper chamber.
Migrating macrophages were counted in three random 100
microscopic ﬁelds per well at 6 hours after seeding (for IC-
21 macrophages) and at 20 hours after seeding (for primary
mouse peritoneal macrophages). Three independent exper-
iments were performed for each assay.
Mouse I.P. Xenograft Models
Four-week-old female nude mice were purchased from the
National Cancer Institute (Frederick, MD) and inoculated
i.p. with 1.5  106 cells of MOSEC and 2  106 SKOV3ip
lines (nZ 5 mice per group). Mice were euthanized by CO2
asphyxiation at times indicated in the legend of Figure 1 or
when morbid ascites had developed. Cells were collected
from ascites by centrifugation. Solid tumor tissue sections
were formalin ﬁxed and parafﬁn embedded.ajp.amjpathol.org - The American Journal of Pathology
HOXA9 Stimulates TAMsIHC Data
Staining of formalin-ﬁxed, parafﬁn-embedded tissue sections
with Abs was detected by streptavidin-biotin-peroxidase and
3,30-diaminobenzidine (Dako). Evaluation of staining is
described in the ﬁgure legends.
Flow Cytometric Analysis
Ascitic cells from xenograft models and cultured peritoneal
macrophages were incubated with Abs to F4/80 and CD206
(1:20) for 30 minutes at 4C, washed, and then incubated
with phycoerythrin-conjugated anti-rabbit Ab and peridinin-
chlorophyll-protein complex-conjugated anti-rat Ab to
detect staining of F4/80 and CD206, respectively. After
washing, cells were ﬁxed in 4% paraformaldehyde and
staining was analyzed by ﬂow cytometry (FACS Calibur;
BD Biosciences).
ELISA Data
Levels of CCL2, TGF-b2, IL-10, and CCL17 in ascites ﬂuid
and in tumor-conditioned medium were assayed by enzyme-
linked immunosorbent assay (ELISA), according to the
manufacturer’s instructions (R&D Systems).
RT-qPCR
Transcripts were analyzed by using SYBR Green qPCR
Master Mix (SA Biosciences, Valencia, CA) and the
following primers: human CCL2, 50-AGAATCACCAGC-
AGCAAGTGTCC-30 (forward) and 50-TCCTGAACCC-
ACTTCTGCTTGG-30 (reverse); mouse Il10, 50-CGGGAA-
GACAATAACTGCACCC-30 (forward) and 50-CGGTT-
AGCAGTATGTTGTCCAGC-30 (reverse); mouse Ccl17,
50-CGAGAGTGCTGCCTGGATTACT-30 (forward) and
50-GGTCTGCACAGATGAGCTTGCC-30 (reverse); mouse
Il12a, 50-ACGAGAGTTGCCTGGCTACTAG-30 (forward)
and 50-CCTCATAGATGCTACCAAGGCAC-30 (reverse);
mouse Mrc1, 50-GTTCACCTGGAGTGATGGTTCTC-30
(forward) and 50-AGGACATGCCAGGGTCACCTTT-30
(reverse); and mouse Cd163, 50-GGCTAGACGAAGTCA-
TCTGCAC-30 (forward) and 50-CTTCGTTGGTCAGCCT-
CAGAGA-30 (reverse). RPL32 (human) and Rpl32 (mouse)
transcript levels were used as controls for normalization and
were detected using primers previously described.14
ChIP Assay
Chromatin immunoprecipitation (ChIP) assays were performed
using the EZ-ChIP Assay kit (Millipore, Temecula, CA).
Sheared chromatin was incubated overnight with 1 mg of
HOXA9 Ab. DNA was puriﬁed from precipitated complexes
and used to amplify a 407-bp fragment of the CCL2 promoter
using the following primers: forward, 50-TAACCCAGGCT-
TGTGCCGAGAT-30; and reverse, 50-CTTTGCTGGCTGA-
GTGTTCACATA-30. A 166-bp fragment of the GAPDH geneThe American Journal of Pathology - ajp.amjpathol.orgwas ampliﬁed as an irrelevant control using the following
primers: forward, 50-TACTAGCGGTTTTACGGGCG-30; and
reverse, 50-TCGAACAGGAGGAGCAGAGAGCGA-30.
Statistics
Statistical analysis was performed using STATISTICA
software version 10 (StatSoft Inc., Tulsa, OK). Values of
statistical signiﬁcance of data were assessed by unpaired
two-tailed Student’s t-test, unless noted otherwise. Data
represent means  SD. P < 0.05 was considered signiﬁcant.
Correlation coefﬁcients were determined by Spearman test.
Results
HOXA9 Expression Is Associated with Abundance of M2
Macrophages in I.P. Xenograft Models of Ovarian
Cancer
Based on our recent ﬁndings that HOXA9 expression in
ovarian cancer cells only promotes tumor growth in vivo, but
not in vitro,14 we hypothesized that HOXA9 could modulate
tumor-host cell interactions. Because the peritoneal cavity is
the most commonly involved site in ovarian cancer and is a
macrophage-rich environment, we investigated whether
HOXA9 expression is associated with increased macrophage
inﬁltration. Macrophages were detected by F4/80 staining in
omental implants of mouse i.p. xenograft models generated
from control and HOX-overexpressing MOSEC ovarian
cancer cell lines that we previously established.13 Although
only a few macrophages were detected in tumors derived
from vector-control MOSEC cells, signiﬁcantly more mac-
rophages were detected in tumors derived fromMOSEC cells
that stably expressed HOXA9 (þHOXA9) (P < 0.001)
(Figure 1, A and B). The HOXA10 and HOXA11 genes are
expressed in a subset of ovarian cancers and are thought to
have evolved by gene duplication from the same ancestral
gene as HOXA9.10,13 In contrast to þHOXA9 MOSEC xe-
nografts, the numbers of inﬁltrating macrophages in MOSEC
xenografts that expressed HOXA10 or HOXA11 were not
signiﬁcantly different from those in vector-control xenografts
(Figure 1, A and B). These ﬁndings indicate that HOXA9
expression in ovarian cancer cells is associated with the
abundance of tumor-inﬁltrating macrophages and that this
characteristic is not shared with other related HOX proteins.
To evaluate the phenotype of macrophages in xenograft
models, we analyzed the expression of the mannose receptor,
CD206, a commonly used mouse M2 macrophage marker,
within the population of F4/80þ macrophages in ascites by
ﬂow cytometry. As shown in Figure 1C, the proportion of
macrophages that expressed CD206 was nearly fourfold
higher in theþHOXA9MOSEC xenograft model than in the
vector-control MOSECmodel. To conﬁrm these ﬁndings in a
different model system, we analyzed ascitic macrophages
in i.p. xenograft models generated from previously estab-
lished þHOXA9 control and HOXA9 shRNA-expressing273
Ko et alSKOV3ip ovarian cancer cell lines.14 HOXA9 levels in the
HOXA9-knockdown SKOV3ip lines (shA9-A and shA9-B)
were 25% of the HOXA9 levels in control SKOV3ip lines
(that expressed empty vector or nontargeting shRNA).14 We
previously found that HOXA9 stimulates ovarian tumor
growth in vivo, thereby accelerating the development of
morbid ascites and decreasing survival times.14 We, there-
fore, analyzed ascitic macrophages of sacriﬁced mice at two
different time points after tumor cell inoculation: at 25 days
when morbid ascites had developed in the control groups and274then at 45 days when morbid ascites had developed in the
HOXA9-knockdown groups. At the earlier time point (day
25), the proportions of CD206þ ascitic macrophages in the
HOXA9-knockdown groups were 20% to 25% of the pro-
portions found in the control groups (Figure 1D). Even at the
later time point (day 45), the HOXA9-knockdown groups
still had lower proportions of CD206þ ascitic macrophages
than those in the control groups at day 25 (Figure 1D). These
observations indicate that high HOXA9 levels in ovarian
cancer cells are associated with an increased abundance of
M2 macrophages at the equivalent stage of disease.
Secreted Factors Derived from HOXA9-Expressing
Ovarian Cancer Cells Directly Stimulate Peritoneal
Macrophages to Acquire M2 Features
In addition to macrophages, the tumor stroma is composed
of various cellular elements.1,2 We investigated whether
HOXA9-expressing ovarian cancer cells directly stimulate
peritoneal macrophages to acquire an M2 phenotype indepen-
dently of effects of other stromal cells. Primary cultures of naïve
mouse peritoneal macrophages were stimulated with medium
that had been conditioned by equivalent numbers of cells of
þHOXA9 control and HOXA9-knockdown SKOV3ip lines.
Because the in vitro proliferation rates of control and HOXA9-
knockdown SKOV3ip lines are identical,14 this approach also
enabled us to compare the direct effects of these tumor lines on
macrophages, independently of any differences in tumor cell
growth. As shown by ﬂow cytometric analysis in Figure 2A,
CD206 expression was more strongly induced in peritoneal
macrophages after stimulation with medium conditioned by
control SKOV3ip lines than with medium conditioned by
HOXA9-knockdown SKOV3ip lines. This difference in
CD206 inductionwas conﬁrmed by quantitative RT-PCR (RT-
qPCR) analysis (Figure 2B). Furthermore, expression of the
scavenger receptor, CD163, another M2 marker, was more
strongly induced in peritoneal macrophages after stimulation
with medium conditioned by control SKOV3ip cells than withFigure 1 HOXA9 expression is associated with abundance of M2 mac-
rophages in i.p. xenograft models of ovarian cancer. AeC: Mouse i.p.
xenograft models were established from vector-control and HOX-
overexpressing MOSEC lines. Mice were sacriﬁced at 2 months after tumor
cell inoculation. A: Representative examples of staining of F4/80þ mac-
rophages in omental implants. Scale barZ 50 mm. B: Average numbers of
F4/80þ cells in omental implants were calculated by scoring ﬁve random
200 microscopic ﬁelds of stained tumor tissue sections of each mouse (n
Z 5 mice per group). ***P < 0.001. C: Ascitic cells of vector-control and
þHOXA9 MOSEC xenograft models were stained with Abs to F4/80 and
CD206 and evaluated by ﬂow cytometric analysis. Shown are representative
examples of the proportions of CD206þ cells within the gated population of
F4/80þ macrophages. D: Mouse i.p. xenograft models were established
from þHOXA9 control (empty vector and nontargeting) and HOXA9-
knockdown (shA9-A and shA9-B) SKOV3ip lines. CD206 expression was
evaluated by ﬂow cytometric analysis in ascitic macrophages of control and
HOXA9-knockdown groups of mice that were sacriﬁced at 25 days after
tumor cell inoculation. Other HOXA9-knockdown groups of mice were
analyzed at 45 days after tumor cell inoculation.
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Figure 2 HOXA9 expression in ovarian cancer cells stimulates peritoneal macrophages to acquire M2 features. Primary cultures of naïve mouse peritoneal
macrophages were stimulated with nonconditioned (No. cond.) medium and with medium conditioned by equivalent numbers of cells of þHOXA9 control
(empty vector and nontargeting) and HOXA9-knockdown (shA9-A and shA9-B) SKOV3ip lines. At 5 days thereafter, macrophages were evaluated for expression
of M2 markers, cytokines, and chemokines. A: Flow cytometric analysis of CD206 expression. B: RT-qPCR analysis of expression of Mrc1 (encoding CD206) and
Cd163. C: RT-qPCR analysis of Il10, Ccl17, and Il12a expression. *P < 0.005, **P < 0.001.
HOXA9 Stimulates TAMsmedium conditioned by HOXA9-knockdown SKOV3ip cells
(P < 0.001) (Figure 2B).
M2 macrophage polarization is characterized by elevated
expression of immunosuppressive factors, such as IL-10 and
CCL17, and reduced expression of immunostimulatory cy-
tokines, such as IL-12.3,4 Expression of Il10 and Ccl17 was
more strongly induced in primary mouse peritoneal macro-
phages after stimulation with medium conditioned by control
SKOV3ip cells than with medium conditioned by HOXA9-
knockdown SKOV3ip cells (P < 0.01) (Figure 2C).
Conversely, IL12a expression was signiﬁcantly lower in
macrophages that were stimulated with control SKOV3ip
cell-conditioned medium than in macrophages stimulated
with medium conditioned by HOXA9-knockdown SKOV3ip
cells (P < 0.01) (Figure 2C). These ﬁndings indicate that
HOXA9-High ovarian cancer cells are more effective than
HOXA9-Low tumor cells in stimulating naïve peritoneal
macrophages to acquire features of M2 macrophages.
Stimulatory Effects of HOXA9 on Macrophages Are Not
Solely Due to HOXA9-Induced, Tumor-Derived TGF-b2
Levels
Based on our recent ﬁnding that the TGFB2 gene is a direct
transcriptional target of HOXA9,14 we investigated theThe American Journal of Pathology - ajp.amjpathol.orgpossibility that the ability of HOXA9 to induce M2 features
in peritoneal macrophages is due to HOXA9-mediated in-
duction of tumor-derived TGF-b2 levels. To investigate this
possibility, we compared the effects of control SKOV3ip
cells (nontargeting), HOXA9-knockdown SKOV3ip cells
(shA9-B), and a previously established TGF-b2eknockdown
SKOV3ip line (shTGF-b2), which expresses TGF-b2 at the
same low level as HOXA9-knockdown SKOV3ip cells.14
The TGF-b2 levels in media conditioned by nontargeting,
shA9-B, and shTGF-b2 SKOV3ip cells were 231 14, 59
7, and 41 24 pg/mL, respectively.14As shown in Figure 3A,
medium conditioned by TGF-b2eknockdown SKOV3ip
cells was less effective than medium conditioned by control
SKOV3ip cells in inducing CD206 expression in primary
mouse peritoneal macrophages. However, medium condi-
tioned by HOXA9-knockdown SKOV3ip cells was even
less effective in inducing CD206 expression in primary
macrophages (Figure 3A). Similar results were obtained in
assays using the peritoneal macrophage cell line, IC-21
(Supplemental Figure S1A). Conversely, we tested the ef-
fect of reconstituting TGF-b2 in eHOXA9 tumor cells by
using a previously established HOXA9-knockdown SKO-
V3ip line in which TGFB2 cDNA was stably expressed
(shA9-BþTGF-b2).14 This cell line expresses TGF-b2 at the
same high level as control SKOV3ip cells (in which TGF-b2275
Figure 3 Stimulatory effects of HOXA9 on macrophages are only partially mediated by HOXA9-induced, tumor-derived TGF-b2 levels. A: Primary cultures of
naïve mouse peritoneal macrophages were stimulated with medium conditioned by control (nontargeting), TGF-b2eknockdown (shTGF-b2), and HOXA9-
knockdown (shA9-B) SKOV3ip lines and an HOXA9-knockdown line that stably expressed TGF-b2 (shA9-B þ TGF-b2). Macrophages were also stimulated
with recombinant TGF-b2 (rTGF-b2) at the same concentration as that released by control SKOV3ip cells (240 pg/mL). At 5 days thereafter, macrophages were
evaluated for CD206 expression by ﬂow cytometric analysis. B: Chemotaxis of primary mouse peritoneal macrophages toward cells of the indicated SKOV3ip
lines was assayed at 20 hours after seeding in Transwell chambers. Macrophages were also stimulated with rTGF-b2, as described for A. Shown are average
results of three independent experiments. C and D: Mouse i.p. xenograft models were established from vector-control and þHOXA9 MOSEC lines and a þHOXA9
MOSEC line in which TGF-b2 was knocked down (þHOXA9þ shTGF-b2), and were evaluated at 2 months after tumor cell inoculation. C: Average numbers of F4/
80þ cells in omental implants were calculated by scoring ﬁve random 200 microscopic ﬁelds of stained tumor tissue sections of each mouse (nZ 5 mice per
group). D: Representative examples of staining of F4/80þ macrophages in omental implants. *P < 0.0005, **P < 0.01, ***P < 0.001. Scale bar Z 50 mm.
Ko et allevels in media conditioned by shA9-B þ TGF-b2 and non-
targeting SKOV3ip cells are 240  35 and 231  14 pg/mL,
respectively14). Reconstitution of TGF-b2 in HOXA9-
knockdown SKOV3ip cells increased CD206 expression in
macrophages, but this induction was only 60% of the level
induced by control SKOV3ip cells (Figure 3A). Similarly,
stimulation of macrophages with recombinant TGF-b2 at the
same concentration as that released by control SKOV3ip cells
induced CD206 expression to a level that was only 50% of the
level induced by medium conditioned by control SKOV3ip
cells (Figure 3A).
We also evaluated whether macrophage chemotaxis is
stimulated by tumor-derived TGF-b2 levels that are
induced by HOXA9. Chemotaxis of primary mouse peri-
toneal macrophages toward SKOV3ip cells was partially
inhibited when TGF-b2 was knocked down in SKOV3ip
cells, and was more strongly inhibited when HOXA9 was
knocked down (Figure 3B). Reconstitution of TGF-b2 in
HOXA9-knockdown SKOV3ip cells increased macrophage
chemotaxis, but not to the level seen with þHOXA9276control SKOV3ip cells (Figure 3B). Identical results were
obtained in chemotaxis assays using IC-21 macrophages
(Supplemental Figure S1B). To investigate the effects of
inhibiting TGF-b2 in þHOXA9 tumor cells in vivo, we
evaluated the numbers of inﬁltrating macrophages in
xenografts generated from vector-control and þHOXA9
MOSEC cell lines and from a previously generated
þHOXA9 MOSEC line that stably expressed Tgfb2 shRNA
(þHOXA9 þ shTGF-b2) (in which TGF-b2 levels in
vector-control, þHOXA9, and þHOXA9 þ shTGF-b2
MOSEC cells are 105  6, 417  96, and 108  30 pg/mL,
respectively14). Compared with þHOXA9 MOSEC xeno-
grafts, fewer macrophages were detected in þHOXA9
MOSEC xenografts in which TGF-b2 was knocked down,
but the abundance of macrophages was not as low as that
seen in vector-control (ie, -HOXA9) xenografts (Figure 3,
C and D). Together, our ﬁndings indicate that the stimu-
latory effects of HOXA9 on macrophage chemotaxis and
M2 transition are mediated, in part, but not solely, by the
ability of HOXA9 to induce tumor-derived TGF-b2 levels.ajp.amjpathol.org - The American Journal of Pathology
Figure 4 HOXA9 induces CCL2 expression in
ovarian cancer cells and correlates with levels of
CCL2, TGF-b2, and M2 cytokines in patient ascites.
A: Relative CCL2 mRNA levels in SKOV3ip lines. B:
Detection of binding of endogenous HOXA9 in
SKOV3ip cells to the CCL2 promoter by ChIP.
Negative controls included IP using cells express-
ing HOXA9 shRNA (shA9-B) and IgG. GAPDH was
ampliﬁed as an irrelevant gene control. C: CCL2
levels in media conditioned (cond.) by SKOV3ip
lines. Shown are average results of ELISAs using
three independent sets of each type of SKOV3ip-
conditioned medium. D: CCL2 levels in ascites
ﬂuid of mouse i.p. xenograft models established
from vector-control and HOX-expressing MOSEC
lines (n Z 5 mice per group). E: Relative HOXA9
mRNA levels in ovarian tumor tissues and levels of
CCL2, TGF-b2, IL-10, and CCL17 in matching
specimens of ascites ﬂuid from the same patients
(n Z 14 cases). Correlations were determined by
Spearman test. All cases were postmenopausal
patients with FIGO stage III/IV, high-grade ser-
ous ovarian carcinoma. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0005.
HOXA9 Stimulates TAMsHOXA9 Induces CCL2 Expression in Ovarian Cancer Cells
and Correlates with Levels of CCL2, TGF-b2, and M2
Cytokines in Patient Ascites
We recently identiﬁed TGF-b2 as one of only few tumor-
derived cytokines or chemokines whose expression is
induced by HOXA9, and demonstrated that HOXA9 bound
to the TGFB2 promoter.14 Another chemokine whose ex-
pression was modulated by HOXA9 is CCL2. Knockdown of
HOXA9 in SKOV3ip cells signiﬁcantly down-regulated
CCL2 RNA levels (P < 0.0005) (Figure 4A). A putative
HOXA9-binding site was identiﬁed in the CCL2 promoter at
2.5 kb upstream of the transcription start site. Binding of
endogenous HOXA9 to this site was detected by ChIP assays
in control SKOV3ip cells, but no binding was detected in
HOXA9-knockdown SKOV3ip cells (Figure 4B). Knock-
down of HOXA9 in SKOV3ip cells also signiﬁcantly
inhibited CCL2 protein levels (P < 0.01) (Figure 4C).
Conversely, CCL2 levels in ascites ﬂuid were elevated in
þHOXA9MOSEC xenograft models compared with vector-
control models (P < 0.05), but were not elevated in theThe American Journal of Pathology - ajp.amjpathol.orgþHOXA10 or þHOXA11 xenograft models (Figure 4D).
These ﬁndings indicate that HOXA9, but not other related
HOX proteins, induces CCL2 expression in ovarian cancer
cells. Levels of HOXA9 expression in ovarian tumor tissues
correlated with CCL2 levels in matching specimens of
ascites ﬂuid from the same patients (rs Z 0.68, P Z 0.01)
(Figure 4E). Consistent with our previous ﬁnding that
HOXA9 induces TGF-b2 expression,14 levels of HOXA9
expression in human tumor specimens also correlated with
TGF-b2 levels in the ascites ﬂuid (rs Z 0.57, P Z 0.01)
(Figure 4E). Furthermore,HOXA9 expression levels in tumor
specimens correlated with levels of the M2 cytokines, IL-10
and CCL17, in ascites ﬂuid (rs Z 0.63 for IL-10 and rs Z
0.50 for CCL17, PZ 0.01) (Figure 4E).
Combination of TGF-b2 and CCL2 Can Recapitulate the
Effects of HOXA9 on Macrophages
Because reconstituting TGF-b2 in HOXA9-knockdown tu-
mor cells alone did not completely restore the macrophage-
stimulatory effect of HOXA9, we evaluated the effect of277
Ko et alreconstituting CCL2. Compared with chemotaxis of primary
mouse peritoneal macrophages toward control SKOV3ip cells,
macrophage chemotaxis toward HOXA9-knockdown SKO-
V3ip cellswas partially restored by the addition of recombinantFigure 5 Combination of TGF-b2 and CCL2 recapitulates the stimulatory
effects of HOXA9 on macrophages. A: Chemotaxis of primary mouse peritoneal
macrophages toward þHOXA9 control (nontargeting) and HOXA9-knockdown
(shA9-B) SKOV3ip cells. Where indicated, recombinant TGF-b2 (rTGF-b2) and
CCL2 were added to achieve ﬁnal concentrations of these factors that were the
same as those secreted by nontargeting cells [ie, 240 pg/mL of TGF-b214 and200
pg/mLof CCL2 (refer toFigure4C)]. *P< 0.0005,**P<0.005, and***P< 0.01.
B: Primary cultures of naïvemouse peritonealmacrophageswere stimulatedwith
medium conditioned by SKOV3ip lines. Where indicated, conditioned medium
was reconstitutedwith TGF-b2 and CCL2, as described forA. At 5 days thereafter,
macrophages were evaluated for CD206 expression by ﬂow cytometric analysis.
278CCL2 at the same concentration as that released by control
SKOV3ip cells (Figure 5A). Macrophage chemotaxis was
almost completely restored by the addition of both CCL2 and
TGF-b2 (Figure 5A). Similarly, CD206 induction in primary
mouse peritoneal macrophages was partially restored when
medium conditioned by HOXA9-knockdown tumor cells was
reconstituted with either CCL2 or TGF-b2, but was almost
completely restored by the addition of both factors together
(Figure 5B). Similar results were obtained in chemotaxis and
CD206 induction assays using IC-21 macrophages
(Supplemental Figure S2, A and B). These ﬁndings indicate
that the ability ofHOXA9 to stimulatemacrophage chemotaxis
and M2 transition is largely because of the combinatorial ef-
fects of TGF-b2 and CCL2 levels that are induced byHOXA9.
High HOXA9 Expression in Human Ovarian Cancer
Specimens Is Associated with Increased Abundance of
M2 Macrophages and Treg Cells and Decreased
Abundance of CD8þ TILs
To evaluate whether high HOXA9 levels are associated with
increased macrophage inﬁltration and increased proportions
of M2 macrophages in human tumors, we collected a ho-
mogenous set of omental metastasis specimens from a group
of patients with stage III/IV, high-grade serous ovarian
carcinoma and performed immunohistochemical (IHC)
analysis. The numbers of macrophages that were detected
by CD68 staining in tumors that highly expressed HOXA9
were signiﬁcantly higher than those detected in tumors that
expressed low levels of HOXA9 (P < 0.01) (Figure 6, A
and B). CD163 is commonly used as a human M2 macro-
phage marker.9,16,17 The proportion of macrophages that
expressed CD163 was signiﬁcantly higher in HOXA9-High
tumors than in HOXA9-Low tumors (P < 0.01) (Figure 6,
A and B). TAMs stimulate recruitment of Treg cells that
inhibit effector T-cell activity.3,4 More Treg cells were
detected by FOXP3 staining in HOXA9-High tumors than
in HOXA9-Low tumors (P < 0.05) (Figure 6, A and B).
Conversely, HOXA9-High tumors contained signiﬁcantly
fewer CD8þ tumor-inﬁltrating lymphocytes (TILs) than
HOXA9-Low tumors (P < 0.01) (Figure 6, A and B). These
observations indicate that high HOXA9 expression in
ovarian cancer is associated with increased abundance of
M2 macrophages and Treg cells and with decreased abun-
dance of TILs.Discussion
Increasing evidence indicates that cross talk between tumor
and stromal cells plays an important role in tumor pro-
gression and that this cross talk is regulated by pathways
that normally control developmental patterning. For ex-
ample, the notch, hedgehog, and Wnt signaling pathways
are activated in many types of tumors, and these develop-
mental pathways modulate interactions of tumor cells withajp.amjpathol.org - The American Journal of Pathology
Figure 6 High HOXA9 expression in human
ovarian cancer specimens is associated with
increased abundance of M2 macrophages and Treg
cells and decreased abundance of CD8þ TILs. A:
IHC analysis of omental tumors from patients with
FIGO stage III/IV, high-grade serous ovarian car-
cinoma. Cases with no or weak HOXA9 staining
were scored as HOXA9-Low (n Z 9). Cases with
strong HOXA9 staining were scored as HOXA9-High
(n Z 16). Shown are representative examples of
weak and strong HOXA9 staining in omental tu-
mors of two different cases. Also shown are spec-
imens of the same cases stained with Abs to CD68,
CD163, FOXP3, and CD8. Scale bar Z 50 mm. B:
Numbers of tumor-inﬁltrating CD68þ, CD163þ,
FOXP3þ, and CD8þ cells were counted in ﬁve
random 200 microscopic ﬁelds of stained tissue
sections of each case. Average numbers of CD68þ,
FOXP3þ, and CD8þ cells are shown for cases
grouped by HOXA9 expression, with each symbol
representing an individual case. The percentage of
macrophages that were CD163þ was calculated
from the numbers of CD163þ and CD68þ cells per
ﬁeld for a given case. The statistical signiﬁcance of
differences between groups of cases was deter-
mined by U-test. *P < 0.05, **P < 0.01, yP <
0.005, and zP < 0.002.
HOXA9 Stimulates TAMsstromal ﬁbroblasts and endothelial cells.18e20 Homeobox
genes are an important class of patterning regulators that
have been increasingly reported to modulate tumor pro-
gression. Many of the homeobox genes studied have been
found to alter tumor cell growth in vitro,21e23 suggesting
that these genes control tumor celleautonomous mecha-
nisms. In this study, we demonstrated that expression of
HOXA9, a homeobox gene that is strongly associated with
poor prognosis in patients with ovarian cancer, stimulates
chemotaxis of peritoneal macrophages and acquisition by
macrophages of M2 features. These results indicate that
sustained HOXA9 expression in ovarian cancer might pro-
mote disease progression by stimulating recruitment of
peritoneal macrophages and by educating macrophages to-
ward a TAM-like phenotype.
It is generally accepted that TAMs have a polarized M2
macrophage phenotype. The most well-studied cytokines
that induce M2-type polarization are IL-4, IL-10, and
IL-13.3,4 TAMs in ovarian tumors have been thought to be
primarily regulated by IL-10, because IL-4 and IL-13 wereThe American Journal of Pathology - ajp.amjpathol.orgundetectable or detected at only low levels in patient asci-
tes.9,24 Our studies indicate that HOXA9 expression in
ovarian cancer cells stimulates macrophage chemotaxis and
M2-like polarization via its induction of tumor-derived
TGF-b2 and CCL2 levels. CCL2 is known to stimulate
monocyte mobilization and has been reported to induce M2-
type features.25 However, to our knowledge, our study is the
ﬁrst to report that TGF-b2 stimulates macrophage chemo-
taxis and M2 polarization. It has been recently demonstrated
that the TGFB2 and CCL2 genes are direct transcriptional
targets of HOXA9.14,26 Our ﬁndings support a model in
which the stimulatory effects of HOXA9 on TAMs are
largely due to the combinatorial effects of TGF-b2 and
CCL2, but the possibility that HOXA9 controls macrophage
chemotaxis and polarization by regulating other transcrip-
tional targets cannot be excluded. Presently, it is not possible to
conclude that the stimulatory effect of HOXA9 on TAMs is
restricted to ovarian cancer. HOXA9 has also been reported to
bind the CCL2 promoter in astrocytoma cells,26 raising the
possibility thatHOXA9might also exert stimulatory effects on279
Ko et alTAMs in cancers of other organ sites. However, HOX pro-
teins function in a context-dependent manner.10 Indeed,
HOXA9 has been reported to exert a tumor-suppressive ef-
fect in breast cancer.27 A given HOX protein might exert
different effects by controlling distinct sets of transcriptional
targets in different cell types or contexts.
Because tumor progression is dynamically orchestrated
by cross talk between tumor cells, TAMs, and various other
cell types, the ability of HOXA9 to induce TGF-b2 and
CCL2 levels and to stimulate TAMs could substantially
amplify tumor-promoting signals in the tumor microenvi-
ronment. CCL2 stimulates monocyte recruitment to tumors
and promotes mobilization of mesenchymal stem cells
(MSCs).28 We have demonstrated that ovarian tumore
derived TGF-b2 stimulates normal MSCs to transition into
cancer-associated ﬁbroblasts (CAFs) that highly express
TGF-b2 and IL-6.14 IL-6 has been reported to induce M2-
type polarization of macrophages.9,25 HOXA9 might,
therefore, stimulate TAMs through the direct effects of
tumor-derived TGF-b2 and CCL2 levels on macrophages
and promote CAFs that express factors that, in turn, stim-
ulate macrophages in a paracrine manner. Reciprocally,
HOXA9-mediated stimulation of macrophages might also
promote CAFs because macrophage-derived factors can
stimulate MSC mobilization.28
A major mechanism by which TAMs promote tumor
progression is by suppressing adaptive immunity. TAMs are
characterized by high expression of IL-10 and low levels of
IL-12, and these cytokines inhibit and stimulate T-cell
proliferation, respectively.3,4 In addition to IL-10, TAMs
highly express chemokines, such as CCL17 and CCL22,
that recruit Treg cells, which, in turn, suppress effector T-
cell activity.3,4 TAM-derived factors also suppress anti-
tumor immunity by inducing naïve T-cell anergy, skewing
T cells toward a type 2 helper T-cell direction and inhibiting
dendritic cell maturation.3,4 Treg cells have been found to
contribute to ovarian tumor growth by suppressing tumor-
speciﬁc immunity and to be predictive of poor survival.29
Conversely, increased numbers of CD8þ TILs are associ-
ated with favorable prognosis in patients with ovarian can-
cer.30 Our study demonstrates that high HOXA9 levels in
ovarian cancer are strongly associated with increased
abundance of TAMs, with increased numbers of Treg cells,
and with decreased numbers of TILs. These observations are
consistent with the ability of TAMs to stimulate Treg cell
recruitment, and support a model in which the association of
HOXA9 with poor outcomes is linked to the ability of
HOXA9 to promote a TAM-abundant, immunosuppressive
microenvironment. TGF-b signaling controls expression of
FOXP3 that plays an essential role in Treg cell differentiation
and function.31,32 CCL2 stimulates Treg recruitment to tu-
mors.33 HOXA9-induced levels of TGF-b2 and CCL2might,
therefore, have direct stimulatory effects on Treg cells and
indirect effects through TAMs. Reciprocally, increased
abundance of Treg cells could promote TAMs because Treg
cells highly express IL-4, IL-10, and IL-13.34 Also, TAMs280highly express angiogenic factors and matrix metal-
loproteinases.4,5 We have found that þHOXA9 ovarian
tumor xenografts have high microvessel density and in-
creased propensity for i.p. dissemination.14 It is, therefore,
possible that the TAM-inducing ability of HOXA9 promotes
ovarian tumor progression by stimulating tumor angiogenesis
and invasiveness, as well as through immunosuppression.
In summary, our study demonstrates the signiﬁcance of a
developmental gene in regulating tumor cell interactions
with macrophages. TAMs represent an attractive target for
cancer therapy. Several agents that inhibit CCL2 production
or signaling have been evaluated in preclinical studies.35,36
Varieties of agents that inhibit TGF-b signaling have been
evaluated in preclinical models and clinical trials and
include ligand traps, antisense oligonucleotides, and recep-
tor kinase inhibitors.37 Targeting TAMs has a particularly
strong application to ovarian cancer, because it is associated
with ascites, which is predominantly composed of macro-
phages. Our study raises the possibility that a combination
of agents that block both CCL2 and TGF-b signaling could
be an effective approach to inhibit TAMs in ovarian cancer.
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